

Brussels, **XXX**
SANTE/12894/2019 CIS
(POOL/E5/2019/12894/12894-EN
CIS.docx)
[...](2020) **XXX** draft

COMMISSION IMPLEMENTING REGULATION (EU) .../...

of **XXX**

**concerning the authorisation of a preparation of endo-1,4-beta-xylanase produced by
Aspergillus oryzae (DSM 26372) as a feed additive for laying hens (holder of
authorisation DSM Nutritional Products Sp. z o.o.)**

(Text with EEA relevance)

COMMISSION IMPLEMENTING REGULATION (EU) .../...

of **XXX**

concerning the authorisation of a preparation of endo-1,4-beta-xylanase produced by *Aspergillus oryzae* (DSM 26372) as a feed additive for laying hens (holder of authorisation DSM Nutritional Products Sp. z o.o.)

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition¹, and in particular Article 9(2) thereof,

Whereas:

- (1) Regulation (EC) No 1831/2003 provides for the authorisation of additives for use in animal nutrition and for the grounds and procedures for granting such authorisation.
- (2) In accordance with Article 7 of Regulation (EC) No 1831/2003, an application was submitted for the authorisation of a preparation of endo-1,4-beta-xylanase produced by *Aspergillus oryzae* (DSM 26372). That application was accompanied by the particulars and documents required under Article 7(3) of that Regulation.
- (3) This application concerns the authorisation of a preparation of endo-1,4-beta-xylanase produced by *Aspergillus oryzae* (DSM 26372) as a feed additive for laying hens, to be classified in the additive category 'zootechnical additives'.
- (4) The European Food Safety Authority ('the Authority') concluded in its opinions of 26 September 2017² and 11 November 2019³ that, under the proposed conditions of use, the preparation of endo-1,4-beta-xylanase produced by *Aspergillus oryzae* (DSM 26372) does not have an adverse effect on animal health, consumer safety or the environment. It also concluded that the additive is considered as a potential respiratory sensitiser and that no conclusion could be drawn on dermal sensitisation potential by the additive. Therefore, the Commission considers that appropriate protective measures should be taken to prevent adverse effects on human health, in particular as regards the users of the additive. The Authority also concluded that the additive showed an effect in improving laying performance. The Authority does not consider that there is a need for specific requirements of post-market monitoring. It also verified the report on the method of analysis of the feed additive in feed submitted by the Reference Laboratory set up by Regulation (EC) No 1831/2003.
- (5) The assessment of the preparation of endo-1,4-beta-xylanase produced by *Aspergillus oryzae* (DSM 26372) shows that the conditions for authorisation, as provided for in

¹ OJ L 268, 18.10.2003, p. 29.

² EFSA Journal 2017;15(10):5020

³ EFSA Journal 2019;17(11):5919.

Article 5 of Regulation (EC) No 1831/2003, are satisfied. Accordingly, the use of that preparation should be authorised as specified in the Annex to this Regulation.

- (6) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS REGULATION:

Article 1

The preparation specified in the Annex, belonging to the additive category ‘zootechnical additives’ and to the functional group ‘digestibility enhancers’, is authorised as an additive in animal nutrition as set out in the Annex.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels,

For the Commission
The President
Ursula VON DER LEYEN